Search results
Showing 721 to 735 of 882 results for community guidance
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
there are many examples in practice that highlight how individuals and communities can positively shape the way that services are...
management programmes promote self-management and are often provided in the community.If found to be effective for endometriosis, pain...
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people
For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo
know how to tailor and deliver messages, for example, to minority ethnic communities, who may have lower vaccination uptake and also be...
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
substantially as a result of an ageing population and better detection in the community.For diagnosis and monitoring, patients have an...
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Evidence-based recommendations on Prontosan for treating acute and chronic wounds.
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.